{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:11:04Z","timestamp":1778271064172,"version":"3.51.4"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project Fund for Excellent Research and Innovation Teams in Universities of Anhui Province","award":["2024AH010032"],"award-info":[{"award-number":["2024AH010032"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This study investigates shared molecular mechanisms between pyoderma gangrenosum (PG) and inflammatory bowel disease (IBD) and systematically evaluates the therapeutic potential of JAK inhibitors targeting this pathway. Despite the clear clinical comorbidity, the core inflammatory pathways driving cross-tissue associations between the two diseases remain unclear. Furthermore, systematic mechanistic evidence is lacking regarding whether JAK inhibitors act by regulating shared pathological pathways in patients with comorbidities. To address this, this study integrated PG skin and IBD intestinal transcriptome data, single-cell transcriptomic data, and genome-wide association study (GWAS) meta-data from public databases. It employed a multi-level computational biology approach combining Mendelian randomization, weighted gene co-expression network analysis, protein interaction network construction, molecular docking simulations, and system dynamics modeling. The results revealed that genetic analysis confirmed IBD as a causal risk factor for PG, precisely identifying six shared genetic loci. Transcriptomic analysis identified a cross-tissue conserved inflammatory module centered on the JAK-STAT pathway, with JAK2 and STAT3 identified as network hubs. Molecular docking predicted high affinity of baricitinib for both JAK1 and JAK2, while system dynamics modeling demonstrated that its intervention effectively suppresses signaling in the shared inflammatory network. This study reveals the molecular basis of the \u201cgut\u2013skin axis\u201d comorbidity between PG and IBD from a multi-omics integration perspective. It provides predictive computational evidence for the use of JAK inhibitors in targeted comorbidity therapy. Baricitinib is identified as a particularly promising candidate. These findings advance the transition from empirical drug use to mechanism-guided precision treatment strategies. Although this study provides multiscale computational simulation evidence, the lack of direct experimental validation of these predicted results necessitates further confirmation through in vitro and in vivo experiments.<\/jats:p>","DOI":"10.3390\/ijms27093733","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:29:03Z","timestamp":1776868143000},"page":"3733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK Inhibitor Targets in PG and IBD"],"prefix":"10.3390","volume":"27","author":[{"given":"Hui","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Wannan Medical University, Wuhu 241000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Wannan Medical University, Wuhu 241000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-0270","authenticated-orcid":false,"given":"Ruzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Wannan Medical University, Wuhu 241000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","article-title":"Pathophysiology of pyoderma gangrenosum (PG): An updated review","volume":"73","author":"Braswell","year":"2015","journal-title":"JAAD"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2036.2004.02055.x","article-title":"Skin complications associated with inflammatory bowel disease","volume":"20","author":"Tavarela","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: A retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: An update on pathophysiology, diagnosis and treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"JAAD"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: Definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"Engl. J. Med."},{"key":"ref_12","first-page":"533","article-title":"Ulcerative and Vegetative Pyoderma Gangrenosum Successfully Treated with Adalimumab: A Case Report","volume":"38","author":"Wang","year":"2024","journal-title":"Chin. J. Dermatovenereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: Clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10620-019-05999-4","article-title":"Pyoderma gangrenosum in inflammatory bowel disease: A systematic review and meta-analysis","volume":"65","author":"States","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/bjd.15226","article-title":"Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)","volume":"176","author":"Marzano","year":"2017","journal-title":"Brit. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: A retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Brit. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41467-018-07841-3","article-title":"Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response","volume":"10","author":"Haberman","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet\u2019s syndrome","volume":"178","author":"Marzano","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: Archive for functional genomics data sets\u2014Update","volume":"41","author":"Barrett","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrg3868","article-title":"Methods of integrating data to uncover genotype\u2013phenotype interactions","volume":"16","author":"Ritchie","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Langfelder, P., and Horvath, S. (2008). WGCNA: An R package for weighted correlation network analysis. BMC Bioinf., 9.","DOI":"10.1186\/1471-2105-9-559"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression","volume":"142","author":"Friedman","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"\u0141yko, M., Rygu\u0142a, A., Kowalski, M., Karska, J., and Jankowska-Konsur, A. (2024). The Pathophysiology and Treatment of Pyoderma Gangrenosum\u2014Current Options and New Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042440"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/bib\/bbaf633","article-title":"Large-scale multi-trait genome-wide analysis for inflammatory bowel disease reveals new insights into its molecular mechanisms and emphasizes the roles of systemic immune regulation","volume":"26","author":"Zhu","year":"2025","journal-title":"Brief. Bioinform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/ijd.17093","article-title":"Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: A case series of 35 patients","volume":"63","author":"Caldarola","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_30","first-page":"550","article-title":"Targeting Cytokines in Inflammatory Bowel Disease","volume":"19","author":"Dubinsky","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/bies.201600008","article-title":"The gut-skin axis in health and disease: A paradigm with therapeutic implications","volume":"38","author":"Monteleone","year":"2016","journal-title":"Bioessays"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, E.A., Steel, A., Luxardi, G., Mitra, A., Patel, F., Cheng, M.Y., Wilken, R., Kao, J., de Ga, K., and Sultani, H. (2018). Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: A hypothesis based on molecular and clinicopathologic studies. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01980"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cui, R., and Zhang, J. (2025). Research progress of SOCS in autoimmune diseases: Mechanisms and therapeutic implications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1604271"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2397477","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: A systematic review and network meta-analysis","volume":"35","author":"Chen","year":"2024","journal-title":"J. Dermatol. Treat"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9646","DOI":"10.2340\/actadv.v103.9646","article-title":"Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: A case report","volume":"103","author":"Kim","year":"2023","journal-title":"Acta Derm-Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase\u2013signal transducers and activators of transcription cell signaling in Spondyloarthritis: Rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00128071-200708020-00002","article-title":"The role of anti-tumor necrosis factor-\u03b1 therapy in pyoderma gangrenosum associated with inflammatory bowel disease","volume":"8","author":"Grange","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL23 is composed of IL12R\u03b21 and a novel cytokine receptor subunit, IL23R","volume":"168","author":"Parham","year":"2002","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2016.10.001","article-title":"Targeting cytokine signaling in autoimmunity: Back to the future and beyond","volume":"43","author":"Hirahara","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","article-title":"Genetics of inflammatory bowel diseases","volume":"149","author":"McGovern","year":"2015","journal-title":"Gastroenterology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:11:12Z","timestamp":1778267472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27093733"],"URL":"https:\/\/doi.org\/10.3390\/ijms27093733","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}